DOP2017000071A - Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace. - Google Patents
Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.Info
- Publication number
- DOP2017000071A DOP2017000071A DO2017000071A DO2017000071A DOP2017000071A DO P2017000071 A DOP2017000071 A DO P2017000071A DO 2017000071 A DO2017000071 A DO 2017000071A DO 2017000071 A DO2017000071 A DO 2017000071A DO P2017000071 A DOP2017000071 A DO P2017000071A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- alzheimer
- combination therapy
- uses anti
- bace inhibitor
- beta plus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Massaging Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar una enfermedad neurodegenerativa o cognitiva, que comprende administrar a un paciente que necesite dicho tratamiento una cantidad eficaz de un compuesto de la fórmula: , o una sal farmacéuticamente aceptable de este; en combinación con una cantidad eficaz de un anticuerpo monoclonal Abeta anti-N3pGlu.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050967P | 2014-09-16 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000071A true DOP2017000071A (es) | 2017-06-15 |
Family
ID=54207720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000071A DOP2017000071A (es) | 2014-09-16 | 2017-03-14 | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9999624B2 (es) |
| EP (1) | EP3193882A1 (es) |
| JP (1) | JP6339741B2 (es) |
| KR (1) | KR101871128B1 (es) |
| CN (1) | CN106687136A (es) |
| AP (1) | AP2017009794A0 (es) |
| AR (1) | AR101740A1 (es) |
| AU (1) | AU2015318257B2 (es) |
| BR (1) | BR112017003571A2 (es) |
| CA (1) | CA2956835A1 (es) |
| CL (1) | CL2017000558A1 (es) |
| CO (1) | CO2017001875A2 (es) |
| CR (1) | CR20170080A (es) |
| DO (1) | DOP2017000071A (es) |
| EA (1) | EA031764B1 (es) |
| EC (1) | ECSP17015977A (es) |
| IL (1) | IL250387A0 (es) |
| MX (1) | MX2017003414A (es) |
| NZ (1) | NZ728636A (es) |
| PE (1) | PE20170464A1 (es) |
| PH (1) | PH12017500493A1 (es) |
| SG (1) | SG11201701330PA (es) |
| SV (1) | SV2017005389A (es) |
| TN (1) | TN2017000072A1 (es) |
| TW (1) | TWI599358B (es) |
| WO (1) | WO2016043997A1 (es) |
| ZA (1) | ZA201700826B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107893A1 (es) * | 2016-03-15 | 2018-06-28 | Astrazeneca Ab | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| WO2018034977A1 (en) | 2016-08-18 | 2018-02-22 | Eli Lilly And Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
| AR110470A1 (es) * | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
| RU2019108717A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов |
| TWI789644B (zh) | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| RU2020118913A (ru) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| US12350278B2 (en) | 2018-06-27 | 2025-07-08 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections in non-human animals |
| US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| CN115443147A (zh) * | 2020-04-23 | 2022-12-06 | 伊莱利利公司 | 抗体的皮下吸收和生物利用度 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| MA71622A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Domaines de liaison à l'antigène cd98hc et leurs utilisations |
| CN119497721A (zh) | 2022-07-29 | 2025-02-21 | 艾莱克特有限责任公司 | 转铁蛋白受体抗原结合结构域及其用途 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534950A1 (en) | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| BRPI0906962B8 (pt) * | 2008-01-18 | 2021-05-25 | Eisai R&D Man Co Ltd | composto de aminodiidrotiazina fundido |
| SI3339323T1 (sl) * | 2010-08-12 | 2019-12-31 | Eli Lilly And Company | Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2015
- 2015-09-01 TW TW104128851A patent/TWI599358B/zh not_active IP Right Cessation
- 2015-09-02 AR ARP150102803A patent/AR101740A1/es unknown
- 2015-09-08 KR KR1020177006748A patent/KR101871128B1/ko not_active Expired - Fee Related
- 2015-09-08 JP JP2017514623A patent/JP6339741B2/ja not_active Expired - Fee Related
- 2015-09-08 BR BR112017003571A patent/BR112017003571A2/pt not_active Application Discontinuation
- 2015-09-08 EA EA201790305A patent/EA031764B1/ru not_active IP Right Cessation
- 2015-09-08 EP EP15771800.8A patent/EP3193882A1/en not_active Withdrawn
- 2015-09-08 CA CA2956835A patent/CA2956835A1/en not_active Abandoned
- 2015-09-08 NZ NZ728636A patent/NZ728636A/en not_active IP Right Cessation
- 2015-09-08 WO PCT/US2015/048807 patent/WO2016043997A1/en not_active Ceased
- 2015-09-08 MX MX2017003414A patent/MX2017003414A/es unknown
- 2015-09-08 TN TN2017000072A patent/TN2017000072A1/en unknown
- 2015-09-08 CR CR20170080A patent/CR20170080A/es unknown
- 2015-09-08 AU AU2015318257A patent/AU2015318257B2/en not_active Ceased
- 2015-09-08 PE PE2017000406A patent/PE20170464A1/es unknown
- 2015-09-08 AP AP2017009794A patent/AP2017009794A0/en unknown
- 2015-09-08 US US15/503,027 patent/US9999624B2/en not_active Expired - Fee Related
- 2015-09-08 CN CN201580049574.0A patent/CN106687136A/zh active Pending
- 2015-09-08 SG SG11201701330PA patent/SG11201701330PA/en unknown
-
2017
- 2017-02-01 IL IL250387A patent/IL250387A0/en unknown
- 2017-02-02 ZA ZA2017/00826A patent/ZA201700826B/en unknown
- 2017-02-22 SV SV2017005389A patent/SV2017005389A/es unknown
- 2017-02-24 CO CONC2017/0001875A patent/CO2017001875A2/es unknown
- 2017-03-08 CL CL2017000558A patent/CL2017000558A1/es unknown
- 2017-03-14 DO DO2017000071A patent/DOP2017000071A/es unknown
- 2017-03-15 PH PH12017500493A patent/PH12017500493A1/en unknown
- 2017-03-15 EC ECIEPI201715977A patent/ECSP17015977A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017000558A1 (es) | 2017-11-10 |
| ZA201700826B (en) | 2018-12-19 |
| MX2017003414A (es) | 2017-06-19 |
| WO2016043997A1 (en) | 2016-03-24 |
| US20170224702A1 (en) | 2017-08-10 |
| KR101871128B1 (ko) | 2018-06-25 |
| SV2017005389A (es) | 2018-01-17 |
| EA201790305A1 (ru) | 2017-07-31 |
| PH12017500493A1 (en) | 2017-08-07 |
| AU2015318257A1 (en) | 2017-02-16 |
| AP2017009794A0 (en) | 2017-03-31 |
| CN106687136A (zh) | 2017-05-17 |
| AU2015318257B2 (en) | 2018-06-14 |
| PE20170464A1 (es) | 2017-04-26 |
| JP2017529348A (ja) | 2017-10-05 |
| SG11201701330PA (en) | 2017-04-27 |
| CR20170080A (es) | 2017-03-30 |
| KR20170036103A (ko) | 2017-03-31 |
| TWI599358B (zh) | 2017-09-21 |
| TW201618786A (zh) | 2016-06-01 |
| IL250387A0 (en) | 2017-03-30 |
| US9999624B2 (en) | 2018-06-19 |
| JP6339741B2 (ja) | 2018-06-06 |
| NZ728636A (en) | 2018-05-25 |
| BR112017003571A2 (pt) | 2017-12-19 |
| ECSP17015977A (es) | 2018-03-31 |
| EA031764B1 (ru) | 2019-02-28 |
| EP3193882A1 (en) | 2017-07-26 |
| TN2017000072A1 (en) | 2018-07-04 |
| CO2017001875A2 (es) | 2017-05-19 |
| AR101740A1 (es) | 2017-01-11 |
| CA2956835A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170080A (es) | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| LT3416631T (lt) | Terapiniai agentai, skirti neurodegeneracinių ligų gydymui | |
| CU24498B1 (es) | Anticuerpos de factor xi | |
| HUE053239T2 (hu) | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére | |
| EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
| MX2018009175A (es) | Agonista fxr derivado de esteroides. | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| IL239981B1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
| CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
| IL287832A (en) | Methods of administering anti-cd38 antibody to treat multiple myeloma | |
| EP3718531A4 (en) | LIQUID PREPARATION OF A HUMANIZED ANTIBODY FOR THE TREATMENT OF IL-6-RELATED DISEASES | |
| WO2016069477A3 (en) | A method of treating cancer that overexpresses topbp1 | |
| EA201792282A1 (ru) | Способы лечения заболеваний | |
| MX2024008671A (es) | Metodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina. | |
| BR112018002763A2 (pt) | método para cicatrização de ferimentos | |
| MX2022005245A (es) | Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer. | |
| MX2017003140A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| MX391162B (es) | Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5 |